TY - JOUR
T1 - Superoxide induces protein oxidation in plasma and TNF-α elevation in macrophage culture
T2 - Insights into mechanisms of neurotoxicity following doxorubicin chemotherapy
AU - Keeney, Jeriel T.R.
AU - Miriyala, Sumitra
AU - Noel, Teresa
AU - Moscow, Jeffrey A.
AU - St. Clair, Daret K.
AU - Butterfield, D. Allan
N1 - Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
PY - 2015/10/28
Y1 - 2015/10/28
N2 - Chemotherapy-induced cognitive impairment (CICI) is a quality of life-altering consequence of chemotherapy experienced by a large percentage of cancer survivors. Approximately half of FDA-approved anti-cancer drugs are known to produce ROS. Doxorubicin (Dox), a prototypical ROS-generating chemotherapeutic agent, generates superoxide (O2-) via redox cycling. Our group previously demonstrated that Dox, which does not cross the BBB, induced oxidative damage to plasma proteins leading to TNF-α elevation in the periphery and, subsequently, in brain following cancer chemotherapy. We hypothesize that such processes play a central role in CICI. The current study tested the notion that O2- is involved and likely responsible for Dox-induced plasma protein oxidation and TNF-α release. Addition of O2- as the potassium salt (KO2) to plasma resulted in significantly increased oxidative damage to proteins, indexed by protein carbonyl (PC) and protein-bound HNE levels. We then adapted this protocol for use in cell culture. Incubation of J774A.1 macrophage culture using this KO2-18crown6 protocol with 1 and 10 M KO2 resulted in dramatically increased levels of TNF-α produced. These findings, together with our prior results, provide strong evidence that O2- and its resulting reactive species are critically involved in Dox-induced plasma protein oxidation and TNF-α release.
AB - Chemotherapy-induced cognitive impairment (CICI) is a quality of life-altering consequence of chemotherapy experienced by a large percentage of cancer survivors. Approximately half of FDA-approved anti-cancer drugs are known to produce ROS. Doxorubicin (Dox), a prototypical ROS-generating chemotherapeutic agent, generates superoxide (O2-) via redox cycling. Our group previously demonstrated that Dox, which does not cross the BBB, induced oxidative damage to plasma proteins leading to TNF-α elevation in the periphery and, subsequently, in brain following cancer chemotherapy. We hypothesize that such processes play a central role in CICI. The current study tested the notion that O2- is involved and likely responsible for Dox-induced plasma protein oxidation and TNF-α release. Addition of O2- as the potassium salt (KO2) to plasma resulted in significantly increased oxidative damage to proteins, indexed by protein carbonyl (PC) and protein-bound HNE levels. We then adapted this protocol for use in cell culture. Incubation of J774A.1 macrophage culture using this KO2-18crown6 protocol with 1 and 10 M KO2 resulted in dramatically increased levels of TNF-α produced. These findings, together with our prior results, provide strong evidence that O2- and its resulting reactive species are critically involved in Dox-induced plasma protein oxidation and TNF-α release.
KW - Cancer chemotherapy
KW - Chemotherapy induced cognitive impairment
KW - Macrophage
KW - Superoxide free radical and doxorubicin induced oxidative stress
KW - Tumor necrosis factor-alpha
UR - http://www.scopus.com/inward/record.url?scp=84939258319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939258319&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2015.07.023
DO - 10.1016/j.canlet.2015.07.023
M3 - Article
C2 - 26225838
AN - SCOPUS:84939258319
SN - 0304-3835
VL - 367
SP - 157
EP - 161
JO - Cancer Letters
JF - Cancer Letters
IS - 2
ER -